Volume 65, Issue 4, Pages (April 2004)

Slides:

Advertisements

Similar presentations

Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers Francesco Galli, Serena Benedetti, Ardesio Floridi,

Advertisements

Third-party Mesenchymal Stem Cells Improved Human Islet Transplantation in a Humanized Diabetic Mouse Model Hao Wu, Di Wen, Ram I Mahato Molecular Therapy

Volume 72, Issue 6, Pages (September 2007)

From: Treatment of Refractory Whipple Disease with Interferon-γ

Beta blockers in the management of chronic kidney disease

Intensive hemodialysis—keeping the faith

Use of hemodialysis and hemoperfusion in poisoned patients

S.J. Nessim, S.V. Jassal, S.V. Fung, C.T. Chan Kidney International

Germaine Wong, Jeremy R. Chapman, Jonathan C. Craig

Naïve and central memory T-cell lymphopenia in end-stage renal disease

Volume 56, Issue 3, Pages (September 1999)

Volume 54, Issue 4, Pages (October 1998)

Intensive hemodialysis—keeping the faith

Volume 80, Issue 10, Pages (November 2011)

Volume 62, Issue 2, Pages (August 2002)

C-reactive protein and dialysis access

Volume 75, Issue 11, Pages (June 2009)

Volume 66, Issue 4, Pages (October 2004)

Volume 70, Pages S21-S25 (December 2006)

Vitamin E–bonded hemodialyzer improves atherosclerosis associated with a rheological improvement of circulating red blood cells Shuzo Kobayashi, Hidekazu.

Volume 59, Issue 3, Pages (March 2001)

Third-party Mesenchymal Stem Cells Improved Human Islet Transplantation in a Humanized Diabetic Mouse Model Hao Wu, Di Wen, Ram I Mahato Molecular Therapy

Cell apoptosis and hemodialysis-induced inflammation

C.-C. Yang, S.-P. Hsu, M.-S. Wu, S.-M. Hsu, C.-T. Chien

Antineutrophil Cytoplasmic Antibody-Associated Renal Vasculitis Treated With Autologous Mesenchymal Stromal Cells: Evaluation of the Contribution of Immune-

The importance of increased dialysis and anemia management for infant survival in pregnant women on hemodialysis Sai Subhodhini Reddy, Jean L. Holley

Volume 54, Issue 2, Pages (August 1998)

Body weight is a fluctuating parameter in hemodialysis patients

Volume 73, Issue 7, Pages (April 2008)

D. Coyne Kidney International Volume 69, Pages S1-S3 (May 2006)

S.J. Nessim, S.V. Jassal, S.V. Fung, C.T. Chan Kidney International

Henle Loop Basement Membrane as Initial Site for Randall Plaque Formation Vincenzo Sepe, MD, PhD (Italy), Gabriella Adamo, MD, Alfredo La Fianza, MD,

Prevention of renal failure: The Malaysian experience

Hypertension promotes integrin expression and reactive oxygen species generation by circulating leukocytes Choong H. Kim, Nosratola D. Vaziri Kidney.

Volume 73, Pages S5-S17 (April 2008)

Blood pressure targets in hemodialysis patients

Evolving characteristics of toxoplasmosis in patients infected with human immunodeficiency virus-1: clinical course and Toxoplasma gondii-specific immune.

Volume 69, Issue 10, Pages (May 2006)

Frank Eitner, Jürgen Floege Kidney International

Osteopontin in diabetic nephropathy: signpost or road?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Alternate-day dialysis may be needed for hemodialysis patients

Hepatitis C treatment in patients with kidney disease

Inflammatory signals associated with hemodialysis

A.K.I. Kuroki, Masayuki Iyoda, Takanori Shibata, Tetsuzo Sugisaki

Volume 60, Issue 6, Pages (December 2001)

Lynda Anne Szczech, Ira L. Lazar Kidney International

Volume 64, Pages S84-S93 (December 2003)

Quality of life in peritoneal dialysis patients: Decline over time and association with clinical outcomes Sr. Anne B. Bakewell, Rob M. Higgins, Mair.

Volume 62, Issue 5, (November 2002)

Volume 54, Issue 5, Pages (November 1998)

Decreased interleukin-18 expression in BAL cells and peripheral blood mononuclear cells in adult cystic fibrosis patients Hans-Peter Hauber, Inga S Beyer,

Daily nocturnal home hemodialysis

Antonio Santoro, Elena Mancini Kidney International

Wei-Teing Chen, Horng-Chin Yan, Fu-Chiu Yu Kidney International

Current status of maintenance hemodialysis in Beijing, China

Volume 20, Issue 4, Pages (April 2012)

Figure 2 CD4+ T-cell subsets fluorescence-activated cell sorting analysis in peripheral blood mononuclear cells of patients with multiple sclerosis treated.

Volume 63, Issue 2, Pages (February 2003)

Volume 65, Issue 2, Pages (February 2004)

Charles A. Herzog Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 68, Issue 1, Pages (July 2005)

Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.

Volume 58, Issue 2, Pages (August 2000)

The International Pediatric Peritonitis Registry: Starting to walk

Antioxidant therapy in hemodialysis patients: a systematic review

Evaluation of the Losartan in Hemodialysis (ELHE) Study

Stephen Pastan, J. Michael Soucie, William M. McClellan

Presentation transcript:

Volume 65, Issue 4, Pages 1473-1481 (April 2004) Vitamin E–loaded dialyzer resets PBMC-operated cytokine network in dialysis patients Carmelo Libetta, Manuela Zucchi, Elena Gori, Vincenzo Sepe, Francesco Galli, Federica Meloni, Fabio Milanesi, Antonio D.A.L. Canton Kidney International Volume 65, Issue 4, Pages 1473-1481 (April 2004) DOI: 10.1111/j.1523-1755.2004.00528.x Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 1 Interferon γ (IFNγ) production by CD4+ of normal subjects (Con), and patients on regular hemodialysis treatment with cellulosic membranes (RDT-CM) and vitamin E–coated membranes (RDT-VE) at 3, 6, and 12months (3m, 6m, and 12 m) of therapy.*Indicates a significant difference between stimulated phytohemagglutinin (PHA+) and unstimulated (PHA-) cells of the same group (P < 0.001 Con; P < 0.01 RDT-VE 3m, RDT-VE 6m and RDT-VE 12m; P < 0.05 RDT-CM). ° Indicates a significant difference vs. stimulated cells of Con (P < 0.01 RDT-CM; P < 0.05 all RDT-VE). °°P < 0.05 vs. stimulated RDT-CM. Kidney International 2004 65, 1473-1481DOI: (10.1111/j.1523-1755.2004.00528.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 2 Interleukin (IL)-4 production by CD4+ of normal subjects (Con), and patients on regular hemodialysis treatment with cellulosic membranes (RDT-CM) and vitamin E–coated membranes (RDT-VE) at 3, 6, and 12months of therapy.*Indicates a significant difference between stimulated phytohemagglutinin (PHA+) and unstimulated (PHA-) cells of the same group (P < 0.001 Con; P < 0.05 all RDT-VE). ° Indicates a significant difference vs. unstimulated cells of Con (P < 0.02 RDT-CM; P < 0.05 all RDT-VE). **P < 0.05 vs. unstimulated RDT-CM. Kidney International 2004 65, 1473-1481DOI: (10.1111/j.1523-1755.2004.00528.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 3 Interleukin (IL)-10 production by CD4+ of normal subjects (Con), and patients on regular hemodialysis treatment with cellulosic membranes (RDT-CM) and vitamin E–coated membranes (RDT-VE) at 3, 6, and 12months of therapy.*Indicates a significant difference between stimulated (PHA+) and unstimulated (PHA-) cells of the same group (P < 0.001 Con; P < 0.05 all RDT). °P < 0.03 vs. unstimulated cells of Con. **P < 0.05 vs. unstimulated RDT-CM. Kidney International 2004 65, 1473-1481DOI: (10.1111/j.1523-1755.2004.00528.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 4 Interleukin (IL)-12 production by peripheral blood mononuclear cells (PBMC) of normal subjects (Con), and patients on regular hemodialysis treatment with cellulosic membranes (RDT-CM) and vitamin E–coated membranes (RDT-VE) at 3, 6, and 12months of therapy.*Indicates a significant difference between stimulated phytohemagglutinin (PHA+) and unstimulated (PHA-) cells of the same group (P < 0.001 Con; P < 0.03 all RDT-VE). °Indicates a significant difference vs. unstimulated cells of Con (P < 0.01 RDT-CM; P < 0.05 all RDT-VE). **P < 0.05 vs. unstimulated RDT-CM. °°Indicates a significant difference vs. stimulated cells of Con (P < 0.01 RDT-CM; P < 0.05 all RDT-VE). §P < 0.05 vs. stimulated RDT-VE. Kidney International 2004 65, 1473-1481DOI: (10.1111/j.1523-1755.2004.00528.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 5 Interleukin (IL)-18 production by peripheral blood mononuclear cells (PBMC) of normal subjects (Con), and patients on regular hemodialysis treatment with cellulosic membranes (RDT-CM) and vitamin E–coated membranes (RDT-VE) at 3, 6, and 12months of therapy.*Indicates a significant difference between stimulated phytohemagglutinin (PHA+) and unstimulated (PHA-) cells of the same group (P < 0.001 Con; P < 0.05 all RDT-VE). ° Indicates a significant difference vs. unstimulated cells of Con (P < 0.01 RDT-CM; P < 0.02 all RDT-VE). **P < 0.05 vs. unstimulated RDT-CM. °°Indicates a significant difference vs. stimulated cells of Con (P < 0.04). §P < 0.05 vs. stimulated RDT-VE6m and RDT-VE12m. Kidney International 2004 65, 1473-1481DOI: (10.1111/j.1523-1755.2004.00528.x) Copyright © 2004 International Society of Nephrology Terms and Conditions

Figure 6 Interferon (IFN)γ/interleukin (IL)-4 ratio of normal subjects (Con), and patients on regular hemodialysis treatment with cellulosic membranes (RDT-CM) and vitamin E–coated membranes (RDT-VE) at 3, 6, and 12months of therapy.° Indicates a significant difference vs. unstimulated cells of Con (P < 0.01 RDT-CM; P < 0.05 all RDT-VE). *Indicates a significant difference vs. stimulated cells of Con (P < 0.01 RDT-CM; P < 0.05 all RDT-VE3m). Kidney International 2004 65, 1473-1481DOI: (10.1111/j.1523-1755.2004.00528.x) Copyright © 2004 International Society of Nephrology Terms and Conditions